Signatera demonstrated a strong ability to predict overall survival, with Signatera-positive patients showing a 9.68 hazard ratio for overall survival compared to Signatera-negative patients. At 36 months, overall survival was 71.80% for Signatera-positive patients versus 96.0% for Signatera-negative patients.